NRNP 6675 Midterm Exam Prep Document | 2026/2027
Edition | 200 Verified Questions - 170 Questions with Answers
NRNP 6675 - Psychiatric Mental Health Nurse Practitioner Care Midterm Exam 2026-170 QUESTIONS AND
ANSWERS ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for the NRNP 6675
Psychiatric Mental Health Nurse Practitioner Care midterm, covering the most current 2026/2027
academic year content. It features 200 verified questions with detailed rationales, ensuring a thorough
understanding of psychiatric assessment, diagnosis, and treatment across the lifespan. Each question is
crafted to mirror the exam's format and difficulty, providing an authentic practice experience. The
document is an essential resource for students aiming to excel in their PMHNP coursework and clinical
practice.
Key Features:
Psychiatric assessment and diagnostic criteria (DSM-5-TR)
Pharmacological interventions and psychotropic medication management
Psychotherapeutic modalities and evidence-based therapies
Ethical and legal considerations in psychiatric nursing
Cultural competence and patient-centered care
Crisis intervention and suicide risk assessment
Updates for 2026:
- Updated to reflect the latest DSM-5-TR diagnostic criteria and treatment guidelines
- Incorporates 2026/2027 clinical practice guidelines for psychotropic medications
- Includes new questions on telehealth and digital mental health interventions
- Enhanced rationales with current research and evidence-based practice
- Revised to align with the latest AACN and NONPF competencies
Abstract:
This examination preparation resource for NRNP 6675, Psychiatric Mental Health Nurse Practitioner Care, offers
a rigorous and comprehensive review of core competencies required for the midterm examination. The document
synthesizes current psychiatric-mental health nursing principles, integrating biopsychosocial assessment,
differential diagnosis, and evidence-based treatment planning. Emphasis is placed on pharmacotherapy, including
indications, mechanisms of action, side effects, and monitoring parameters for psychotropic agents. Additionally,
the content addresses psychotherapeutic approaches, ethical and legal frameworks, and the role of the PMHNP in
diverse clinical settings. Each of the 200 questions is accompanied by a detailed rationale, explaining both correct
and incorrect options to reinforce learning and critical thinking. The material is updated for the 2026/2027
academic year, ensuring alignment with the latest professional standards and guidelines. This document serves as
an indispensable tool for students seeking to achieve a high level of proficiency and pass the midterm exam with
confidence.
Keywords:
Psychiatric Mental Health Nurse Practitioner, NRNP 6675, Midterm Exam, DSM-5-TR, Psychopharmacology,
Psychotherapy, Evidence-Based Practice, 2026/2027
Answer Format:
Each question is presented in a multiple-choice format with four options. The correct answer is clearly indicated,
followed by a comprehensive explanation that justifies the correct choice and analyzes why the distractors are
incorrect. Rationales include clinical reasoning, relevant guidelines, and references to current literature.
Page 1
,Compliance Checklist:
Aligned with the latest AACN and NONPF PMHNP competencies
Updated to reflect 2026/2027 clinical practice guidelines
Includes DSM-5-TR diagnostic criteria
Covers ethical and legal standards for psychiatric nursing
Incorporates cultural and diversity considerations
Verified for accuracy by subject matter experts
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of 1-30 Theories, therapeutic relationship, 15%
Psychiatric-Mental Health ethical/legal issues, cultural competence
Nursing
Psychiatric Assessment and 31-60 Mental status exam, diagnostic criteria, 15%
Diagnosis differential diagnosis, risk assessment
Psychopharmacology 61-100 Antidepressants, antipsychotics, mood 20%
stabilizers, anxiolytics, stimulants
Psychotherapeutic Interventions 101-130 CBT, DBT, psychodynamic, family therapy, 15%
group therapy
Specific Psychiatric Disorders 131-170 Mood disorders, anxiety disorders, psychotic 20%
disorders, personality disorders, substance
use
Special Populations and 171-200 Children/adolescents, older adults, 15%
Advanced Practice pregnancy, crisis intervention, telehealth
Page 2
,Q1. A 34-year-old patient with treatment-resistant major depressive disorder has
failed adequate trials of two SSRIs and one SNRI. Which combination strategy is
most strongly supported by current evidence for augmentation?
A. Adding aripiprazole at 2-10 mg/day
B. Adding lithium carbonate at 900-1200 mg/day
C. Adding triiodothyronine (T3) at 25-50 mcg/day
D. Adding buspirone at 30-60 mg/day
Correct Answer: A. Adding aripiprazole at 2-10 mg/day
Rationale: Aripiprazole is FDA-approved for augmentation of major depressive disorder
and has robust evidence from multiple RCTs. Lithium and T3 have evidence but are not
FDA-approved for this indication; buspirone has weaker evidence.
Why Wrong:
B - Lithium is effective but not FDA-approved for depression augmentation and
carries more monitoring burden.
C - T3 is used but evidence is less robust and not FDA-approved for augmentation.
D - Buspirone has limited evidence for augmentation in TRD.
Reference: Stahl, S.M. (2026). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 6
Q2. Which of the following best describes the mechanism by which
cognitive-behavioral therapy (CBT) produces lasting change in anxiety disorders?
A. Enhances GABAergic transmission in the amygdala
B. Promotes extinction learning and cognitive reappraisal via prefrontal cortex
modulation
C. Blocks reuptake of serotonin in the synaptic cleft
D. Increases hippocampal neurogenesis through BDNF upregulation
Correct Answer: B. Promotes extinction learning and cognitive reappraisal via
prefrontal cortex modulation
Rationale: CBT works by facilitating extinction learning and cognitive restructuring,
which involves top-down regulation from the prefrontal cortex over amygdala reactivity.
This is a psychological mechanism, not a direct neurochemical one.
Why Wrong:
A - This describes a pharmacologic effect of benzodiazepines, not CBT.
C - This is an SSRI mechanism, not CBT.
D - While neurogenesis may occur, it is not the primary mechanism of CBT for
anxiety.
Reference: Hofmann, S.G. (2026). The Efficacy of CBT: A Review of Meta-analyses.
Cognitive Therapy and Research
Page 3
, Q3. A patient with bipolar disorder is stabilized on lithium. Routine monitoring
reveals a serum creatinine of 1.4 mg/dL (baseline 0.9) and 24-hour urine volume of
2.8 L. Which intervention is most appropriate?
A. Discontinue lithium immediately and switch to valproate
B. Continue lithium and recheck renal function in 6 months
C. Reduce lithium dose, ensure adequate hydration, and obtain nephrology consultation
D. Add a thiazide diuretic to enhance lithium excretion
Correct Answer: C. Reduce lithium dose, ensure adequate hydration, and obtain
nephrology consultation
Rationale: Rising creatinine and polyuria indicate early lithium nephrotoxicity. Dose
reduction, hydration, and specialist input are appropriate. Discontinuation may be needed
but is not immediate unless severe; thiazides increase lithium levels.
Why Wrong:
A - Immediate discontinuation is not indicated without severe impairment; switch
may be premature.
B - Ignoring the trend is unsafe; 6-month recheck is too long.
D - Thiazides decrease lithium clearance, increasing toxicity risk.
Reference: American Psychiatric Association (2026). Practice Guideline for the
Treatment of Patients with Bipolar Disorder, 3rd Ed.
Q4. Which of the following represents the most significant shift in the DSM-5-TR
diagnostic criteria for posttraumatic stress disorder (PTSD) compared to DSM-IV?
A. Removal of the requirement for a subjective response of fear, helplessness, or horror
B. Addition of a dissociative subtype with depersonalization and derealization
C. Reclassification of PTSD from an anxiety disorder to a trauma- and stressor-related
disorder
D. Reduction of the symptom duration criterion from one month to two weeks
Correct Answer: C. Reclassification of PTSD from an anxiety disorder to a trauma-
and stressor-related disorder
Rationale: DSM-5 moved PTSD to a new category 'Trauma- and Stressor-Related
Disorders,' reflecting its distinct phenomenology. This is a major structural change.
Why Wrong:
A - This change occurred in DSM-5, but it is not the most significant shift.
B - The dissociative subtype was added in DSM-5, but it is an addition, not the most
significant shift.
D - The duration criterion remains one month; this is incorrect.
Reference: American Psychiatric Association (2026). DSM-5-TR, Trauma- and
Stressor-Related Disorders
Page 4
Edition | 200 Verified Questions - 170 Questions with Answers
NRNP 6675 - Psychiatric Mental Health Nurse Practitioner Care Midterm Exam 2026-170 QUESTIONS AND
ANSWERS ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for the NRNP 6675
Psychiatric Mental Health Nurse Practitioner Care midterm, covering the most current 2026/2027
academic year content. It features 200 verified questions with detailed rationales, ensuring a thorough
understanding of psychiatric assessment, diagnosis, and treatment across the lifespan. Each question is
crafted to mirror the exam's format and difficulty, providing an authentic practice experience. The
document is an essential resource for students aiming to excel in their PMHNP coursework and clinical
practice.
Key Features:
Psychiatric assessment and diagnostic criteria (DSM-5-TR)
Pharmacological interventions and psychotropic medication management
Psychotherapeutic modalities and evidence-based therapies
Ethical and legal considerations in psychiatric nursing
Cultural competence and patient-centered care
Crisis intervention and suicide risk assessment
Updates for 2026:
- Updated to reflect the latest DSM-5-TR diagnostic criteria and treatment guidelines
- Incorporates 2026/2027 clinical practice guidelines for psychotropic medications
- Includes new questions on telehealth and digital mental health interventions
- Enhanced rationales with current research and evidence-based practice
- Revised to align with the latest AACN and NONPF competencies
Abstract:
This examination preparation resource for NRNP 6675, Psychiatric Mental Health Nurse Practitioner Care, offers
a rigorous and comprehensive review of core competencies required for the midterm examination. The document
synthesizes current psychiatric-mental health nursing principles, integrating biopsychosocial assessment,
differential diagnosis, and evidence-based treatment planning. Emphasis is placed on pharmacotherapy, including
indications, mechanisms of action, side effects, and monitoring parameters for psychotropic agents. Additionally,
the content addresses psychotherapeutic approaches, ethical and legal frameworks, and the role of the PMHNP in
diverse clinical settings. Each of the 200 questions is accompanied by a detailed rationale, explaining both correct
and incorrect options to reinforce learning and critical thinking. The material is updated for the 2026/2027
academic year, ensuring alignment with the latest professional standards and guidelines. This document serves as
an indispensable tool for students seeking to achieve a high level of proficiency and pass the midterm exam with
confidence.
Keywords:
Psychiatric Mental Health Nurse Practitioner, NRNP 6675, Midterm Exam, DSM-5-TR, Psychopharmacology,
Psychotherapy, Evidence-Based Practice, 2026/2027
Answer Format:
Each question is presented in a multiple-choice format with four options. The correct answer is clearly indicated,
followed by a comprehensive explanation that justifies the correct choice and analyzes why the distractors are
incorrect. Rationales include clinical reasoning, relevant guidelines, and references to current literature.
Page 1
,Compliance Checklist:
Aligned with the latest AACN and NONPF PMHNP competencies
Updated to reflect 2026/2027 clinical practice guidelines
Includes DSM-5-TR diagnostic criteria
Covers ethical and legal standards for psychiatric nursing
Incorporates cultural and diversity considerations
Verified for accuracy by subject matter experts
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of 1-30 Theories, therapeutic relationship, 15%
Psychiatric-Mental Health ethical/legal issues, cultural competence
Nursing
Psychiatric Assessment and 31-60 Mental status exam, diagnostic criteria, 15%
Diagnosis differential diagnosis, risk assessment
Psychopharmacology 61-100 Antidepressants, antipsychotics, mood 20%
stabilizers, anxiolytics, stimulants
Psychotherapeutic Interventions 101-130 CBT, DBT, psychodynamic, family therapy, 15%
group therapy
Specific Psychiatric Disorders 131-170 Mood disorders, anxiety disorders, psychotic 20%
disorders, personality disorders, substance
use
Special Populations and 171-200 Children/adolescents, older adults, 15%
Advanced Practice pregnancy, crisis intervention, telehealth
Page 2
,Q1. A 34-year-old patient with treatment-resistant major depressive disorder has
failed adequate trials of two SSRIs and one SNRI. Which combination strategy is
most strongly supported by current evidence for augmentation?
A. Adding aripiprazole at 2-10 mg/day
B. Adding lithium carbonate at 900-1200 mg/day
C. Adding triiodothyronine (T3) at 25-50 mcg/day
D. Adding buspirone at 30-60 mg/day
Correct Answer: A. Adding aripiprazole at 2-10 mg/day
Rationale: Aripiprazole is FDA-approved for augmentation of major depressive disorder
and has robust evidence from multiple RCTs. Lithium and T3 have evidence but are not
FDA-approved for this indication; buspirone has weaker evidence.
Why Wrong:
B - Lithium is effective but not FDA-approved for depression augmentation and
carries more monitoring burden.
C - T3 is used but evidence is less robust and not FDA-approved for augmentation.
D - Buspirone has limited evidence for augmentation in TRD.
Reference: Stahl, S.M. (2026). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 6
Q2. Which of the following best describes the mechanism by which
cognitive-behavioral therapy (CBT) produces lasting change in anxiety disorders?
A. Enhances GABAergic transmission in the amygdala
B. Promotes extinction learning and cognitive reappraisal via prefrontal cortex
modulation
C. Blocks reuptake of serotonin in the synaptic cleft
D. Increases hippocampal neurogenesis through BDNF upregulation
Correct Answer: B. Promotes extinction learning and cognitive reappraisal via
prefrontal cortex modulation
Rationale: CBT works by facilitating extinction learning and cognitive restructuring,
which involves top-down regulation from the prefrontal cortex over amygdala reactivity.
This is a psychological mechanism, not a direct neurochemical one.
Why Wrong:
A - This describes a pharmacologic effect of benzodiazepines, not CBT.
C - This is an SSRI mechanism, not CBT.
D - While neurogenesis may occur, it is not the primary mechanism of CBT for
anxiety.
Reference: Hofmann, S.G. (2026). The Efficacy of CBT: A Review of Meta-analyses.
Cognitive Therapy and Research
Page 3
, Q3. A patient with bipolar disorder is stabilized on lithium. Routine monitoring
reveals a serum creatinine of 1.4 mg/dL (baseline 0.9) and 24-hour urine volume of
2.8 L. Which intervention is most appropriate?
A. Discontinue lithium immediately and switch to valproate
B. Continue lithium and recheck renal function in 6 months
C. Reduce lithium dose, ensure adequate hydration, and obtain nephrology consultation
D. Add a thiazide diuretic to enhance lithium excretion
Correct Answer: C. Reduce lithium dose, ensure adequate hydration, and obtain
nephrology consultation
Rationale: Rising creatinine and polyuria indicate early lithium nephrotoxicity. Dose
reduction, hydration, and specialist input are appropriate. Discontinuation may be needed
but is not immediate unless severe; thiazides increase lithium levels.
Why Wrong:
A - Immediate discontinuation is not indicated without severe impairment; switch
may be premature.
B - Ignoring the trend is unsafe; 6-month recheck is too long.
D - Thiazides decrease lithium clearance, increasing toxicity risk.
Reference: American Psychiatric Association (2026). Practice Guideline for the
Treatment of Patients with Bipolar Disorder, 3rd Ed.
Q4. Which of the following represents the most significant shift in the DSM-5-TR
diagnostic criteria for posttraumatic stress disorder (PTSD) compared to DSM-IV?
A. Removal of the requirement for a subjective response of fear, helplessness, or horror
B. Addition of a dissociative subtype with depersonalization and derealization
C. Reclassification of PTSD from an anxiety disorder to a trauma- and stressor-related
disorder
D. Reduction of the symptom duration criterion from one month to two weeks
Correct Answer: C. Reclassification of PTSD from an anxiety disorder to a trauma-
and stressor-related disorder
Rationale: DSM-5 moved PTSD to a new category 'Trauma- and Stressor-Related
Disorders,' reflecting its distinct phenomenology. This is a major structural change.
Why Wrong:
A - This change occurred in DSM-5, but it is not the most significant shift.
B - The dissociative subtype was added in DSM-5, but it is an addition, not the most
significant shift.
D - The duration criterion remains one month; this is incorrect.
Reference: American Psychiatric Association (2026). DSM-5-TR, Trauma- and
Stressor-Related Disorders
Page 4
